FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1873-1874 November 1, 2007 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: During the past 10 years, there has been a precipitous rise in the number of reports of adverse drug reactions in Malaysia.¹ Of these reports, 20 have involved antiobesity medications, of which only phentermine and orlistat are legally available. Sibutramine, whose approval has been withheld owing to reports of adverse reactions, has been available through the black market.²

The use of the appetite suppressant phenylpropanolamine has been associated with myocardial infarction in patients with angiographically normal coronary arteries.³ To date, no similar data have been reported with regard to phentermine or sibutramine. We report on two otherwise . . . [Full Text of this Article]

This article has been cited by other articles:

• Ernest, D., Gershenzon, A., Corallo, C. E, Nagappan, R. (2008). Sibutramine-Associated QT Interval Prolongation and Cardiac Arrest. The Annals of Pharmacotherapy 42: 1514-1517 [Abstract] [Full Text]